MEDICUS PHARMA LTD. Total Liabilities and Equity
MEDICUS PHARMA LTD. (MDCX) had Total Liabilities and Equity of $27.12 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $27.12M.
- 2026-03-31: Liabilities and Equity $7.43M.
- 2025-12-31: Liabilities and Equity $10.06M.
- 2025-09-30: Liabilities and Equity $9.98M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $27.12M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $7.43M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $10.06M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $9.98M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $11.93M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $5.66M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $5.65M 10-K · filed 2026-03-25 |
| 2023-12-31 | $1.89M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |